Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

1.305 +0.025 (+1.95%)
Streaming Delayed Price Updated: 1:20 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
 
Via Benzinga
Earnings Preview For Ironwood Pharmaceuticals
 
Via Benzinga
Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares jumped 124.2% to $0.1697 after falling 15% on Monday. 
Via Benzinga
Orchestra BioMed, Vital Farms And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Recap: Ironwood Pharmaceuticals Q1 Earnings
 
Via Benzinga
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Earnings Outlook For Ironwood Pharmaceuticals
 
Via Benzinga
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned. 
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Why Ironwood Pharmaceuticals Stock Bumped Higher Today
Investors indicated approval of the company's upcoming $1 billion asset purchase. 
Via The Motley Fool
Ironwood Scoops Up Gastrointestinal Diseases Player For $1B
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has agreed to acquire VectivBio Holding AG (NASDAQ: VECT) for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of... 
Via Benzinga
Why Shares of VectivBio Holding Are Up Today
A buyout offer by Ironwood Pharmaceuticals lifted the clinical-stage biotech's stock. 
Via The Motley Fool
Merger Monday
This morning, Chevron announced a deal to acquire PDC Energy for $72 per share in stock. 
Via Talk Markets
Why VectivBio Shares Are Surging Monday
VectivBio Holding AG (NASDAQ: VECT) shares are trading higher Monday after GI-focused healthcare company Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) agreed to 
Via Benzinga
VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion
Both companies are working on treatments for gastrointestinal diseases. 
Via Investor's Business Daily
Benzinga Pro's Top 5 Stocks To Watch For Monday, May 22, 2023: MU, RKT, DLTR, LDOS, IRWD
Micron Technology (MU) - Shares were down about 4% Monday morning following a report the Chinese government found cybersecurity issues related to Micron's products. Chinese officials have asked 
Via Benzinga
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.